



Determining the Difference between Clinical Research and Quality/Performance Improvement at Memorial University Medical Center

A short questionnaire to identify the appropriate process to follow when beginning a scholarly activity

Let's Get Started.....



This ART is a requirement of all investigators, residents, faculty and others conducting PI/QI activities or research at Memorial University Medical Center. It is intended to: (1) provide a framework for distinguishing QI/PI activities and research projects; (2) provide the process pathway required for each of those; and (3) provide a list of resources available to expedite projects.


The general characteristics of quality/performance improvement and clinical research activities are for use by the Institutional Review Board, administrative reviewers, investigators, and improvers are reviewed here.

Explanation and Elaboration of Terms

- 1. Vulnerable Population.** Any study population that includes students, employees, children, pregnant women, prisoners, active military personnel, individuals who have impaired decision making capacity, or those who are educationally or economically disadvantaged.
- 2. Intent.** The state of the investigator's mind that directs the activity.
- 3. Quality/Performance Improvement.** The combined and unceasing efforts of everyone – healthcare professionals, patients, and their families, researchers, administrators, payers, planners, educators – to make changes that will lead to better patient outcomes, better system performance, and better professional development.
- 4. Clinical Research.** A systematic investigation in a clinical setting designed to develop or contribute to generalizable knowledge (The Common Rule definition of research).

*Ogrinc, G., Nelson, W., Adams, S., O'Hara, A. (2013). An Instrument to Differentiate between Clinical Research and Quality Improvement. *IRB: Ethics & Human Research*. 35(5): 1-8.

Depiction of the continuum of clinical research, quality/performance improvement, and patient care activities



*Ogrinc, G., Nelson, W., Adams, S., O'Hara, A. (2013). An Instrument to Differentiate between Clinical Research and Quality Improvement. *IRB: Ethics & Human Research*. 35(5): 1-8.

Please begin by considering these overarching questions: (Insert Hyperlink Form #1)

1. Will the activities of this project occur within the standard of care? YES NO

If NO, then proceed to Research Process algorithm.

2. Is there risk? YES NO

If YES, use the charts to determine whether this project requires QI/PI review or the Research Process algorithm.

3. Is this project primarily intended to generate generalizable knowledge? YES NO

If YES, proceed to Research Process algorithm.

4. Does this project involve vulnerable populations? YES NO

If YES, use the chart to determine whether this project requires QI/PI review or Research Process algorithm.

5. Does this project require informed consent of the patient? YES NO

If yes, the proceed to Research Process algorithm.

6. Do you intend to publish the results as peer reviewed? YES NO

If yes, this may qualify for either quality/performance improvement and/or research.

*Ogrinc, G., Nelson, W., Adams, S., O'Hara, A. (2013). An Instrument to Differentiate between Clinical Research and Quality Improvement. *IRB: Ethics & Human Research*. 35(5): 1-8.

The following completed forms will be required to submit whether your project is determined to be a quality/performance improvement project or research.

Interpretation

Any checkmarks (even one) in the “Clinical Research” column indicates that there are components of clinical research in the proposed activity. The IRB or QI/PI mentors should initiate a discussion with the investigator or improver to clarify the proposal. In an activity such a public health practice, program evaluation, or quality/performance improvement includes a research component, then IRB review should occur under current federal guidelines and the policies of the institution.

*Ogrinc, G., Nelson, W., Adams, S., O'Hara, A. (2013). An Instrument to Differentiate between Clinical Research and Quality Improvement. *IRB: Ethics & Human Research*. 35(5): 1-8.

(Insert Hyperlink Form #2)


Attribute	QI/PI Improvement	Clinical Research with Human Subjects
<p>Intent and Background</p>	<ul style="list-style-type: none"> <input type="checkbox"/> Describes the nature and severity of a specific local performance gap <input type="checkbox"/> Focus is to improve a specific aspect of health or health care delivery that is currently NOT consistently and appropriately being implemented at this site 	<ul style="list-style-type: none"> <input type="checkbox"/> Identifies a specific deficit in scientific knowledge from the literature <input type="checkbox"/> Proposes to address or identify specific hypotheses
<p>Methods</p>	<ul style="list-style-type: none"> <input type="checkbox"/> Mechanisms of the intervention are expected to change over time (i.e., an iterative activity) in response to ongoing feedback <input type="checkbox"/> Plan for intervention and analysis includes an assessment of the system (i.e., process flow diagram, fishbone, etc.) <input type="checkbox"/> Statistical methods evaluate system level processes and outcomes over time with statistical process controls or other methods 	<ul style="list-style-type: none"> <input type="checkbox"/> Specific protocol defines the intervention, interaction, and use of collected data and tissues, plus project may rely on the randomization of individuals to enhance confidence in differences <input type="checkbox"/> May use qualitative or quantitative methods to make observations, make comparisons between groups, or generate hypotheses <input type="checkbox"/> Statistical methods primarily compare differences between groups or correlate observed differences with a known health condition
<p>Intended Benefit</p>	<ul style="list-style-type: none"> <input type="checkbox"/> Intervention would be considered within the usual clinician-patient therapeutic relationship <input type="checkbox"/> Direct benefit to participants is indicated (e.g., for the decrease in risk by receiving a vaccination or by creating a safer institutional system) <input type="checkbox"/> Potential local institutional benefit is specified (e.g., increased efficiency or decreased cost) 	<ul style="list-style-type: none"> <input type="checkbox"/> Intervention, interaction, or use of identifiable private information occurs outside of the usual clinician-patient therapeutic relationship <input type="checkbox"/> Direct benefit to each individual participant or for the institution is not typically the intent or is not certain <input type="checkbox"/> Potential societal benefit in developing or advancing existing generalized knowledge

*Ogrinc, G., Nelson, W., Adams, S., O'Hara, A. (2013). An Instrument to Differentiate between Clinical Research and Quality Improvement. *IRB: Ethics & Human Research*, 35(5), 1-8.


(Insert Hyperlink Form #3)

Attribute	QI/PI Improvement	Clinical Research with Human Subjects
<p>Risk</p>	<p><input type="checkbox"/> Risk is to privacy or the confidentiality of health information</p> <p><input type="checkbox"/> Risk may be described as high for patients by not participating in this activity</p>	<p><input type="checkbox"/> Risks may be minimal, but may include physical, psychological, emotional, social, or financial risks, as well as risk to privacy or the confidentiality of health information from participation in the project</p> <p><input type="checkbox"/> The informed consent process describes the risks to participants, who individually and voluntarily decide whether to participate or an IRB grants an alteration or waiver of the consent process</p>
<p>Applicability of Results</p>	<p><input type="checkbox"/> Mechanisms of the intervention are expected to change over time (i.e., an iterative activity) in response to ongoing feedback</p> <p><input type="checkbox"/> Extrapolation of results to other settings is possible, but not the main intent of the activity</p>	<p><input type="checkbox"/> Results and analysis may be delayed or periodic throughout the duration of the project, expect to protect patient safety. The results will primarily be used to inform further investigations, but may be implemented directly into clinical practice</p> <p><input type="checkbox"/> Results are intended to generalize beyond the study population</p>
<p>Sharing & Disseminating</p>	<p><input type="checkbox"/> System level outcomes, processes, refinement of the intervention, and the applicability of the intervention in specific settings/contexts may be shard through peer-reviewed publication and presentation outside the institution</p>	<p><input type="checkbox"/> It is expected that results will be published or presented to others through a peer-reviewed process</p>


Six Sigma Quality/Performance Improvement Project Roadmap



**PDSA
Quality/Performance
Improvement
Model**



**Research
Process
Algorithm
Part I**




Research
Process
Algorithm Part
II

Prepare IRB Forms:


- [Original Research Protocol Submission](#)
- [Research Application Checklist](#)
- [Conflict of Interest \(all investigators\)](#)

Prepare other documentation:


- [NIH Training Certificate \(all investigators\)](#)
- Current CV (all investigators)
- Full protocol – See examples under "[Research](#)"
- Synopsis
- Data Collection Form
- Consent form (if applicable) – [Title page](#), [Body](#), [HIPAA Authorization](#), [ICF COI Language](#)
- [Budget](#) (if you're requesting funding)
- Grant Award notice (if applicable)
- Drug/Device information (if applicable)



Research Process Algorithm Part III



**Research
Process
Algorithm Part
IV**



Who is available to help me navigate this process?

Quality/Performance

Improvement

Contact	E-mail	Phone Number
Jean Wiggins, Medical Education	wiggije1@memorialhealth.com	912-350-8168
Maribeth Schaefer, Sr. Process Excellence Consultant	schaema1@memorialhealth.com	912-667-3405
Tammy Kicklighter, HIPAA Compliance Officer	kicklta1@memorialhealth.com	912-350-3314

Research

Contact	E-mail	Phone Number
Mary Ann Beil, Executive Director-Corporate Ethics	beilma1@memorialhealth.com	912-350-5193
Christopher Newman, IRB Administrator	newmach3@memorialhealth.com	912-350-6866
Pat Sharpe, Manager-Clinical Trials	sharppa1@memorialhealth.com	912-350-7887
Eric Shaw, Assoc. Prof. Community Medicine	Shaw_ek@mercer.edu	912-350-1729

Reminders:



- **Form must be completed and included in the Research Proposal or QI/PI Charter**
- **Form must include all appropriate signatures**
- **Contact Patricia Sharpe (Research), Jean Wiggins (Medical Education Administration), or Maribeth Schaefer (Process Excellence) with questions or concerns about the process**